Small molecule · Antagonist of acetylcholine receptor · developed by Journey
Glycopyrronium is a competitive antagonist of acetylcholine receptors on sweat glands. Applied topically as wipes or cloth, it reduces sweating in primary axillary hyperhidrosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 21, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02553798 | Phase 3 | Hyperhidrosis | Completed | DERM |
| NCT03880266 | Phase 2 | Palmar Hyperhidrosis | Completed | DERM |
| NCT02129660 | Phase 2 | Hyperhidrosis | Completed | DERM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HyperhidrosisPalmar Hyperhidrosis
Updated Oct 3, 2026. Something wrong or missing? Report it on the DERM page.
See DERM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
DERM catalysts and pipeline →